RS Components (RS), the trading brand of Electrocomponents plc, the global distributor for engineers, has raised more than £90,000 since April this year - and is set to smash its £150,000 target by April 2018 - after choosing Children with Cancer UK (CWC UK) as its national charity for the 2018 financial year.
RS employees have taken part in a wide range of activities to fundraise for CWC UK, which is the leading national charity dedicated to the fight against childhood cancer. These have included them taking on mountains in the Yorkshire Three Peaks Challenge, being knocked off their perch into cold waters in the Rutland Water Aqua Park Challenge and jumping from a plane in a skydive. Additionally, a team of 25 people from RS are signed up to run in the challenging London Marathon in April 2018.
Mike England, head of region for Northern Europe, said: “Our partnership with Children with Cancer UK started back in April this year, and we’re delighted to have raised so much already to help meet our ambitious target to raise £150,000 in 12 months for this very worthy cause. Our staff at RS have been amazing at embracing the cause, and have been organising lots of activities to raise funds. As well as the big challenges, there are many other team and individual activities that are all contributing to this fantastic effort. I am really proud of the team and their achievements.”
Every day more than 10 children and young people in the UK are diagnosed with cancer, but eight of those ten can be successfully treated, thanks to the research that Children with Cancer UK helps fund.
Jayne Falconer, corporate partnerships manager at Children with Cancer UK, said: “We have been blown away by RS Components’ motivation, energy and determination to raise money for the 4,000 children who are diagnosed with cancer every year. Staff have shown their commitment by taking on epic challenges and holding wonderful events such as their Big Bash and Golf Day to help raise as much money as possible. With RS Components’ help, we can keep families together longer by investing in visionary research to accelerate breakthroughs in cancer treatment and care.”